LENZ THERAPEUTICS, INC. Investing Cash Flow
LENZ THERAPEUTICS, INC. (LENZ) reported Investing Cash Flow of $70.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $37.75M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $33.16M, a 75.56% increase year-over-year.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$89.81M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$4.33M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$75.67M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$154.48M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$29.62M.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$241.86M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $37.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $70.92M 10-Q · filed 2026-08-11 | -$18.89M derived: sum of 3 quarters · filed 2026-08-11 | -$23.23M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $33.16M 10-Q · filed 2026-05-11 | -$56.65M derived: sum of 2 quarters · filed 2026-05-11 | -$60.98M derived: sum of 3 quarters · filed 2026-05-11 | -$61.40M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$89.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$94.14M derived: sum of 2 quarters · filed 2026-03-24 | -$94.56M derived: sum of 3 quarters · filed 2026-08-11 | -$75.67M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | -$4.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.75M derived: sum of 2 quarters · filed 2026-08-11 | $14.14M 10-Q · filed 2025-11-05 | $2.28M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $18.48M 10-Q · filed 2026-08-11 | $6.61M derived: sum of 3 quarters · filed 2026-08-11 | -$55.61M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $18.89M 10-Q · filed 2026-05-11 | $7.03M derived: sum of 2 quarters · filed 2026-05-11 | -$55.20M derived: sum of 3 quarters · filed 2026-05-11 | -$153.59M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$11.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$74.09M derived: sum of 2 quarters · filed 2026-03-24 | -$172.48M derived: sum of 3 quarters · filed 2026-03-24 | -$154.48M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$62.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$160.62M derived: sum of 2 quarters · filed 2025-11-05 | -$142.62M 10-Q · filed 2025-11-05 | -$127.44M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$98.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$80.39M 10-Q · filed 2025-07-30 | -$65.22M derived: sum of 3 quarters · filed 2025-07-30 | -$83.13M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | $18.00M 10-Q · filed 2025-05-07 | $33.17M derived: sum of 2 quarters · filed 2025-05-07 | $15.26M derived: sum of 3 quarters · filed 2025-05-07 | -$11.62M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$2.74M derived: sum of 2 quarters · filed 2025-03-19 | -$29.61M derived: sum of 3 quarters · filed 2025-03-19 | -$29.62M 10-K · filed 2025-03-19 | $226.35M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$17.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$44.79M derived: sum of 2 quarters · filed 2024-11-06 | -$44.79M 10-Q · filed 2024-11-06 | $179.26M 10-Q · filed 2023-11-13 | -$31.27M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$26.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$26.88M 10-Q · filed 2024-08-14 | $115.39M 10-Q · filed 2023-08-14 | -$13.36M derived: sum of 3 quarters · filed 2024-08-14 | -$9.86M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | -$6.00K 10-Q · filed 2024-05-08 | $43.16M 10-Q · filed 2023-05-11 | $13.52M derived: sum of 2 quarters · filed 2024-05-08 | $17.01M derived: sum of 3 quarters · filed 2024-05-08 | -$71.20M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $17.02M derived: sum of 2 quarters · filed 2024-02-27 | -$71.20M derived: sum of 3 quarters · filed 2024-02-27 | -$241.86M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$84.72M derived: sum of 2 quarters · filed 2023-11-13 | -$255.39M 10-Q · filed 2023-11-13 | -$256.37M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$88.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$258.88M 10-Q · filed 2023-08-14 | -$259.86M derived: sum of 3 quarters · filed 2023-08-14 | -$263.50M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$170.67M 10-Q · filed 2023-05-11 | -$171.65M derived: sum of 2 quarters · filed 2023-05-11 | -$175.28M derived: sum of 3 quarters · filed 2023-05-11 | -$176.05M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$981.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$4.62M derived: sum of 2 quarters · filed 2023-03-20 | -$5.38M derived: sum of 3 quarters · filed 2023-03-20 | -$5.74M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$4.40M derived: sum of 2 quarters · filed 2022-11-09 | -$4.76M 10-Q · filed 2022-11-09 | -$5.37M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$763.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.12M 10-Q · filed 2022-08-11 | -$1.74M derived: sum of 3 quarters · filed 2022-08-11 | -$2.29M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$360.00K 10-Q · filed 2022-05-12 | -$972.00K derived: sum of 2 quarters · filed 2022-05-12 | -$1.53M derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | -$612.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$1.17M derived: sum of 2 quarters · filed 2022-03-21 | -$1.54M 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | -$554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$933.00K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | -$379.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |